The median progression free survival was @ months on sorafenib vs. @ months on S+C / T ( p = @ ) and there was no significant difference of overall survival between two arms ( p = @ ) with median overall survival @ months under sorafenib vs. @ months on S+C / T. Patients remained on trial for a median of @ cycles on sorafenib and @ cycles on S+C / T.